Recent Advances in Immunotherapy and Resistance Mechanism for Liver Cancer

Articles

ORIGINAL RESEARCH

Published on 22 Nov 2023

Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients with transarterial chemoembolization- refractory hepatocellular carcinoma: a two-center retrospective study

CASE REPORT

Published on 10 Oct 2023

Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report

ORIGINAL RESEARCH

Published on 12 May 2023

Metabolic syndrome is independently associated with improved overall survival to first-line therapy with immune checkpoint inhibitors in non-small cell lung cancer

ORIGINAL RESEARCH

Published on 03 May 2023

Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization

SYSTEMATIC REVIEW

Published on 27 Apr 2023

Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis

Share on

Frontiers in Oncology

Submit your idea

Articles

Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients with transarterial chemoembolization- refractory hepatocellular carcinoma: a two-center retrospective study

Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report

Metabolic syndrome is independently associated with improved overall survival to first-line therapy with immune checkpoint inhibitors in non-small cell lung cancer

Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization

Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis

Frontiers in Oncology